Investors focused on the Medical space have likely heard of TG Therapeutics (TGTX), but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
TG Therapeutics is a member of the Medical sector. This group includes 841 individual stocks and currently holds a Zacks Sector Rank of #1. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. TGTX is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for TGTX's full-year earnings has moved 24.55% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, TGTX has moved about 8.05% on a year-to-date basis. At the same time, Medical stocks have gained an average of 3.81%. As we can see, TG Therapeutics is performing better than its sector in the calendar year.
Breaking things down more, TGTX is a member of the Medical - Products industry, which includes 77 individual companies and currently sits at #83 in the Zacks Industry Rank. On average, stocks in this group have gained 2.46% this year, meaning that TGTX is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track TGTX. The stock will be looking to continue its solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report TG Therapeutics, Inc. (TGTX): Get Free Report To read this article on Zacks.com click here. Zacks Investment Research